Douglass Winthrop Advisors’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$832K Hold
5,967
0.02% 173
2025
Q4
$732K Sell
5,967
-3,000
-33% -$365K 0.01% 181
2025
Q3
$995K Buy
8,967
+2,817
+46% +$320K 0.02% 154
2025
Q2
$682K Sell
6,150
-350
-5% -$37.2K 0.01% 169
2025
Q1
$728K Sell
6,500
-525
-7% -$54.2K 0.01% 158
2024
Q4
$649K Sell
7,025
-25
-0.4% -$2.25K 0.01% 177
2024
Q3
$591K Sell
7,050
-48
-0.7% -$3.66K 0.01% 188
2024
Q2
$487K Buy
7,098
+48
+0.7% +$3.2K 0.01% 195
2024
Q1
$516K Sell
7,050
-825
-10% -$63.4K 0.01% 191
2023
Q4
$638K Hold
7,875
0.01% 155
2023
Q3
$590K Hold
7,875
0.01% 151
2023
Q2
$607K Sell
7,875
-400
-5% -$31.9K 0.01% 159
2023
Q1
$687K Sell
8,275
-150
-2% -$12.4K 0.02% 140
2022
Q4
$723K Buy
8,425
+850
+11% +$67.3K 0.02% 140
2022
Q3
$467K Sell
7,575
-25
-0.3% -$1.58K 0.01% 173
2022
Q2
$470K Sell
7,600
-200
-3% -$12.4K 0.01% 181
2022
Q1
$464K Sell
7,800
-4,450
-36% -$284K 0.01% 193
2021
Q4
$889K Buy
12,250
+3,250
+36% +$224K 0.02% 142
2021
Q3
$629K Sell
9,000
-642
-7% -$45.1K 0.02% 171
2021
Q2
$664K Buy
9,642
+492
+5% +$32.9K 0.02% 175
2021
Q1
$591K Sell
9,150
-150
-2% -$9.67K 0.02% 176
2020
Q4
$542K Sell
9,300
-600
-6% -$36.2K 0.02% 179
2020
Q3
$626K Sell
9,900
-495
-5% -$34.3K 0.02% 153
2020
Q2
$800K Sell
10,395
-294
-3% -$22.5K 0.03% 120
2020
Q1
$799K Sell
10,689
-261
-2% -$18K 0.04% 112
2019
Q4
$712K Buy
10,950
+500
+5% +$32.6K 0.03% 153
2019
Q3
$662K Sell
10,450
-195
-2% -$12.7K 0.03% 153
2019
Q2
$719K Sell
10,645
-194
-2% -$12.8K 0.03% 147
2019
Q1
$705K Sell
10,839
-2,600
-19% -$173K 0.03% 135
2018
Q4
$841K Sell
13,439
-50
-0.4% -$3.5K 0.04% 126
2018
Q3
$1.04M Sell
13,489
-1,400
-9% -$106K 0.05% 114
2018
Q2
$1.05M Sell
14,889
-3,200
-18% -$226K 0.05% 145
2018
Q1
$1.36M Sell
18,089
-216
-1% -$17.2K 0.07% 131
2017
Q4
$1.31M Sell
18,305
-4,602
-20% -$349K 0.07% 112
2017
Q3
$1.86M Hold
22,907
0.11% 91
2017
Q2
$1.62M Sell
22,907
-530
-2% -$35.3K 0.1% 90
2017
Q1
$1.59M Sell
23,437
-1,454
-6% -$102K 0.1% 94
2016
Q4
$1.78M Buy
24,891
+617
+3% +$45.9K 0.12% 83
2016
Q3
$1.92M Buy
24,274
+1,366
+6% +$111K 0.13% 79
2016
Q2
$1.91M Sell
22,908
-1,030
-4% -$91.4K 0.13% 79
2016
Q1
$2.2M Sell
23,938
-550
-2% -$49.6K 0.16% 76
2015
Q4
$2.48M Buy
24,488
+1,702
+7% +$177K 0.18% 78
2015
Q3
$2.24M Sell
22,786
-4,225
-16% -$469K 0.18% 80
2015
Q2
$2.65M Hold
27,011
0.21% 73
2015
Q1
$2.65M Buy
27,011
+4,250
+19% +$432K 0.21% 73
2014
Q4
$2.15M Buy
22,761
+1,172
+5% +$121K 0.19% 71
2014
Q3
$2.3M Sell
21,589
-200
-0.9% -$19.6K 0.21% 63
2014
Q2
$1.81M Buy
21,789
+50
+0.2% +$3.89K 0.17% 68
2014
Q1
$1.54M Hold
21,739
0.15% 72
2013
Q4
$1.63M Buy
21,739
+1,400
+7% +$97.5K 0.17% 66
2013
Q3
$1.28M Sell
20,339
-1,111
-5% -$66.4K 0.15% 71
2013
Q2
$1.1M Buy
+21,450
New +$1.12M 0.13% 75

Other funds holding GILD

Douglass Winthrop Advisors's GILD Position: Q1 2026 in Review

Douglass Winthrop Advisors held its Gilead Sciences (GILD) position steady in Q1 2026 at 5,967 shares worth $832K. The position accounts for 0.02% of the portfolio, ranked #173.

Douglass Winthrop Advisors first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.65M in Q2 2015. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Douglass Winthrop Advisors held 5,967 shares of Gilead Sciences worth $832K as of Q1 2026.
  • Douglass Winthrop Advisors left its Gilead Sciences share count unchanged in Q1 2026.
  • Gilead Sciences made up 0.02% of Douglass Winthrop Advisors's portfolio in Q1 2026, its #173 holding.
  • Douglass Winthrop Advisors first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
  • Douglass Winthrop Advisors's Gilead Sciences position peaked at $2.65M in Q2 2015.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Douglass Winthrop Advisors's 13F filing for Q1 2026, filed 14 May 2026.